Your browser doesn't support javascript.
Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity.
Kim, Enoch; Haag, Alyssa; Nguyen, Jackie; Kesselman, Marc M; Demory Beckler, Michelle.
  • Kim E; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States of America. Electronic address: ek617@mynsu.nova.edu.
  • Haag A; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States of America. Electronic address: ah2621@mynsu.nova.edu.
  • Nguyen J; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States of America. Electronic address: jn982@mynsu.nova.edu.
  • Kesselman MM; Division of Rheumatology, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States of America. Electronic address: mkesselman@nova.edu.
  • Demory Beckler M; Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, United States of America. Electronic address: mbeckler@nova.edu.
Mult Scler Relat Disord ; 67: 104172, 2022 Nov.
Статья в английский | MEDLINE | ID: covidwho-2105621
ABSTRACT
Multiple sclerosis (MS) is an incurable autoimmune disease known to cause widespread demyelinating lesions in the central nervous system (CNS) and a host of debilitating symptoms in patients. The development of MS is believed to be driven by the breakdown of the blood brain barrier, subsequent infiltration by CD4+ and CD8+ T cells, and widespread CNS inflammation and demyelination. Disease modifying therapies (DMTs) profoundly disrupt these processes and therefore compose an essential component of disease management. However, the effects of these therapeutic agents on vaccine safety and immunogenicity in individuals with MS are not yet fully understood. As such, the primary objective of this review article was to summarize the findings of recently conducted studies on vaccine safety and immunogenicity in MS patients treated with DMTs, particularly in the context of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Discussed in this review are vaccinations against influenza, yellow fever, human papillomavirus, measles, mumps, rubella, Streptococcus pneumoniae, hepatitis B, and COVID-19. This article additionally reviews our current understanding of COVID-19 severity and incidence in this patient population, the risks and benefits of vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and vaccination guidelines set forth by MS societies and organizations.
Тема - темы
ключевые слова

Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: COVID-19 Vaccines / COVID-19 / Multiple Sclerosis Тип исследования: Наблюдательное исследование / Прогностическое исследование Темы: Вакцина Пределы темы: Люди Язык: английский Журнал: Mult Scler Relat Disord Год: 2022 Тип: Статья

Документы, близкие по теме

MEDLINE

...
LILACS

LIS


Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: COVID-19 Vaccines / COVID-19 / Multiple Sclerosis Тип исследования: Наблюдательное исследование / Прогностическое исследование Темы: Вакцина Пределы темы: Люди Язык: английский Журнал: Mult Scler Relat Disord Год: 2022 Тип: Статья